Overview

A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary antitumor activity of MVC-101
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Maverick Therapeutics, Inc
Takeda